ArticleOncotarget2015
Differentiation between genetic mutations of breast cancer by breath volatolomics.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Diagnostic Power of VOCs Compared With CTCs for Cancer
Diagnosing Cancers From Healthy From Human Exhaled Breath With Na-nose
Who cites it
43 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- eNose technologies in the detection of cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- Advanced strategy for cancer detection based on volatile organic compounds in breath.Journal of nanobiotechnology · 2025Pooled it
- Diagnostic performance of volatile organic compounds analysis and electronic noses for detecting colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Diagnostic Performance of Electronic Noses in Cancer Diagnoses Using Exhaled Breath: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Accuracy of the Electronic Nose Breath Tests in Clinical Application: A Systematic Review and Meta-Analysis.Biosensors · 2021Pooled it
- Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis.JAMA oncology · 2019Pooled it
- Breath based volatile organic compounds in the detection of breast, lung, and colorectal cancers: A systematic review.Cancer biomarkers : section A of Disease markers · 2017Pooled it
- Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules.ACS nano · 2017Pooled it
- Article
- Metabolomics and Biomarker Discovery.Advances in experimental medicine and biology · 2026Review
- The exhaled breath pattern as a potential method for biometrics identification.Scientific reports · 2025Article
- Volatile organic compounds in exhaled breath: Applications in cancer diagnosis and predicting treatment efficacy.Cancer pathogenesis and therapy · 2025Review
- Breathomics: A Non-Invasive Approach for the Diagnosis of Breast Cancer.Bioengineering (Basel, Switzerland) · 2025Review
- Chemical Nose-Based Non-Invasive Detection of Breast Cancer Using Exhaled Breath.Sensors (Basel, Switzerland) · 2025Article
- Artificial Intelligence-Powered Nanosensor Platforms for Non-Invasive Breathomic Diagnostics.Nanotechnology, science and applications · 2025Review
- Article
- Diagnosis of Carcinogenic Pathologies through Breath Biomarkers: Present and Future Trends.Biomedicines · 2023Review
- Article
- Calculations of adsorption-dependent refractive indices of metal-organic frameworks for gas sensing applications.Optics express · 2023Article
- The diagnostic breathprint of cancer; the past and the future.British journal of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mapping molecular sub-types in breast cancer (BC) tumours is a rapidly evolving area due to growing interest in, for example, targeted therapy and screening high-risk populations for early diagnosis. We report a new concept for profiling BC molecular sub-types based on volatile organic compounds (VOCs). For this purpose, breath samples were collected from 276 female volunteers, including healthy, benign conditions, ductal carcinoma in situ (DCIS) and malignant lesions. Breath samples were analysed by gas chromatography mass spectrometry (GC-MS) and artificially intelligent nanoarray technology. Applying the non-parametric Wilcoxon/Kruskal-Wallis test, GC-MS analysis found 23 compounds that were significantly different (p < 0.05) in breath samples of BC patients with different molecular sub-types. Discriminant function analysis (DFA) of the nanoarray identified unique volatolomic signatures between cancer and non-cancer cases (83% accuracy in blind testing), and for the different molecular sub-types with accuracies ranging from 82 to 87%, sensitivities of 81 to 88% and specificities of 76 to 96% in leave-one-out cross-validation. These results demonstrate the presence of detectable breath VOC patterns for accurately profiling molecular sub-types in BC, either through specific compound identification by GC-MS or by volatolomic signatures obtained through statistical analysis of the artificially intelligent nanoarray responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.